#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4506	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2314	569.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1484	1484	C	683	C,T	580,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6778	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3919	516.8	0	.	n	.	0	T695C	SNP	695	695	T	1127	1127	C	496	C,T,A	418,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6778	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3919	516.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1769	1769	A	611	A,G,C	524,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6778	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3919	516.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2403	2403	C	644	C,G	558,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6778	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3919	516.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3029	3029	T	590	T	516	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6778	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3919	516.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2477	2477	A	648	A	556	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	674	folP	852	852	100.0	folP.l6.c4.ctg.1	2271	88.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1520	1522	AGC	164;164;163	A;G;C	135;134;138	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1480	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3891	114.0	1	SNP	p	S91F	0	.	.	271	273	TCC	862	864	TCC	134;134;134	T;C;C	117;117;116	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1480	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3891	114.0	1	SNP	p	D95N	0	.	.	283	285	GAC	874	876	GAC	132;134;135	G;A,T;C,A	118;118,1;118,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1480	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3891	114.0	1	SNP	p	D95G	0	.	.	283	285	GAC	874	876	GAC	132;134;135	G;A,T;C,A	118;118,1;118,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	608	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1612	112.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	617	619	ACC	169;168;167	A;C,A;C	137;139,1;137	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	608	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1612	112.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	632	634	CAC	165;164;164	C,A;A;C	139,1;140;141	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	608	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1612	112.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	815	817	CAC	155;155;155	C;A,C;C	136;136,1;139	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	608	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1612	112.3	1	SNP	p	G45D	0	.	.	133	135	GGC	635	637	GGC	165;166;168	G,T;G;C	136,1;135;139	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	446	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1413	94.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1584	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3359	141.2	1	SNP	p	D86N	0	.	.	256	258	GAC	766	768	GAC	185;183;185	G;A,C;C,T	149;143,1;146,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1584	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3359	141.2	1	SNP	p	S87W	0	.	.	259	261	AGT	769	771	AGT	185;185;184	A,G,C;G;T	146,1,1;153;149	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1584	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3359	141.2	1	SNP	p	S87I	0	.	.	259	261	AGT	769	771	AGT	185;185;184	A,G,C;G;T	146,1,1;153;149	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1584	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3359	141.2	1	SNP	p	S87R	0	.	.	259	261	AGT	769	771	AGT	185;185;184	A,G,C;G;T	146,1,1;153;149	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1584	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3359	141.2	1	SNP	p	S88P	0	.	.	262	264	TCC	772	774	TCC	182;181;180	T;C;C	149;153;148	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1212	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3055	118.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1721	1723	GGC	161;160;160	G;G,T;C,G	134;130,1;135,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1148	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2646	129.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1399	1401	GCA	157;157;157	G;C,A;A	138;134,1;137	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1148	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2646	129.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1402	1404	ATC	157;157;158	A,G;T;C,A	138,1;134;137,2	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1148	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2646	129.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1414	1416	GTG	156;157;157	G;T;G	141;137;137	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1148	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2646	129.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1414	1416	GTG	156;157;157	G;T;G	141;137;137	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1148	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2646	129.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1918	1920	ACC	129;130;129	A;C,A;C	115;115,1;118	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1148	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2646	129.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1972	1974	GCG	130;129;130	G;C,G;G,C	112;106,1;104,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1148	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2646	129.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1972	1974	GCG	130;129;130	G;C,G;G,C	112;106,1;104,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1148	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2646	129.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2095	2097	GGC	137;138;137	G,T;G;C	110,1;121;119	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1148	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2646	129.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2104	2106	GGC	138;137;137	G;G,T;C	118;115,1;120	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1148	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2646	129.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2122	2124	CCG	136;136;136	C;C;G	118;119;114	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1558	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3567	130.8	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1960	1962	CTG	150;149;149	C,T;T;G,T	124,1;127;129,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	906	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2242	121.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	754	754	C	143	C	122	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	172	90.34	porB1a.l15.c17.ctg.1	1118	23.4	0	.	p	.	0	H217N	NONSYN	649	651	CAT	971	973	AAT	8;8;8	A;A;T	6;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	172	90.34	porB1a.l15.c17.ctg.1	1118	23.4	0	.	p	.	0	D218N	NONSYN	652	654	GAT	974	976	AAT	8;8;8	A;A;T	7;7;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	172	90.34	porB1a.l15.c17.ctg.1	1118	23.4	0	.	p	.	0	A222V	NONSYN	664	666	GCT	986	988	GTT	8;8;8	G;T;T	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	172	90.34	porB1a.l15.c17.ctg.1	1118	23.4	0	.	p	.	0	V226A	NONSYN	676	678	GTA	998	1000	GCA	8;8;8	G;C;A	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	172	90.34	porB1a.l15.c17.ctg.1	1118	23.4	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1021	1023	GTA	8;8;8	G;T;A	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	172	90.34	porB1a.l15.c17.ctg.1	1118	23.4	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1033	1033	G	8	G	7	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	780	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1705	133.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	495	497	GGA	157;157;156	G;G;A	133;135;135	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	780	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1705	133.1	0	.	p	.	0	G50N	NONSYN	148	150	GGC	501	503	AAC	156;156;156	A;A;C	132;137;136	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	780	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1705	133.1	0	.	p	.	0	F135L	NONSYN	403	405	TTT	756	758	CTT	140;139;140	C;T;T	111;112;113	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	780	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1705	133.1	0	.	p	.	0	R143G	NONSYN	427	429	AGA	780	782	GGA	135;134;134	G,C;G;A	113,1;111;115	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	780	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1705	133.1	0	.	p	.	0	D171G	NONSYN	511	513	GAT	864	866	GGT	122;123;123	G;G;T	108;108;111	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	780	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1705	133.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	918	920	AGC	138;139;139	A,C;G,A;C,T	118,1;126,1;125,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	780	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1705	133.1	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	984	984	T	147	T	132	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	780	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1705	133.1	1	SNP	p	G120K	0	.	.	358	360	GGT	711	713	GGT	146;145;142	G;G,T;T,G	126;118,1;119,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	780	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1705	133.1	1	SNP	p	A121D	0	.	.	361	363	GCC	714	716	GCC	143;143;143	G,C;C,T;C	117,1;121,1;117	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	780	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1705	133.1	1	SNP	p	A121N	0	.	.	361	363	GCC	714	716	GCC	143;143;143	G,C;C,T;C	117,1;121,1;117	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2852	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5405	158.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2227	2229	AAT	157;157;159	A;A;T,G	134;128;130,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	468	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1308	106.8	1	SNP	p	V57M	1	.	.	169	171	ATG	646	648	ATG	190;191;191	A;T;G	157;164;159	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
